Article Details
Retrieved on: 2024-06-12 16:06:39
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The analyst from Needham highlighted that the key near-term catalyst for Mereo BioPharma's stock is the anticipated interim analysis of the Phase III ...
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here